The epileptic encephalopathies of infancy and childhood

Canadian Journal of Neurological Sciences

Volumn 32, Issue 4, 2005, Pages 409-418

  Wirrell, Elaine ^a,d   Farrell, Kevin ^b   Whiting, Sharon ^c  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d ALBERTA CHILDREN'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BIOTIN; CLOBAZAM; CORTICOSTEROID; CORTICOTROPIN; FELBAMATE; FOLINIC ACID; IMMUNOGLOBULIN; LAMOTRIGINE; PHENOBARBITAL; PIRACETAM; PLACEBO; PREDNISONE; PYRIDOXINE; STIRIPENTOL; SULTIAME; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; BRAIN DISEASE; CHILD; CLINICAL FEATURE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; COMORBIDITY; DISEASE ACTIVITY; DISEASE COURSE; DRAVET SYNDROME; DRUG INDICATION; EARLY DIAGNOSIS; ELECTROENCEPHALOGRAM; EPILEPSY; EPILEPTIC DISCHARGE; EPILEPTIC ENCEPHALOPATHY; FAMILY; HUMAN; INFANT; KETOGENIC DIET; LANDAU KLEFFNER SYNDROME; LENNOX GASTAUT SYNDROME; MYOCLONIC ASTATIC EPILEPSY; NEUROSURGERY; OHTAHARA SYNDROME; ONSET AGE; PRIORITY JOURNAL; PSEUDO LENNOX SYNDROME; RECURRENT DISEASE; REVIEW; SEIZURE; SYSTEMATIC REVIEW; WEST SYNDROME;

EID: 29044448545     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100004388     Document Type: Review

References (117)

1. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:389-399.
2. Aicardi J. Early myoclonic encephalopathy. In: Roger J, Bureau M, Dravet C, Dreifuss FE, Perret A, Wolf P, (Eds). Epileptic Syndromes in Infancy, Childhood and Adolescence, 2 ed. London: John Libbey and Company, 1992:13-23.
3. Ohtahara S, Ohtsuka O, Yamatogi Y, Oka E, Inoue H, Early-infantile epileptic encephalopathy with suppression bursts. In: Roger J, Bureau M, Dravet C, Dreifuss FE, Perret A, Wolf P, (Eds). Epileptic Syndromes in Infancy, Childhood and Adolescence, 2 ed. London: John Libbey and Company, 1992:25-34.
4. Oka E, Ohno M, Minakuchi E, Ohtahara S. Indication of surgery for childhood epilepsy. Jpn J Psychiatry Neurol 1992;46:345-349.
5. Coppola G, Plouin P, Chiron C, Robain O, Dulac O. Migrating partial seizures in infancy: a malignant disorder with developmental arrest. Epilepsia 1995;36:1017-1024.
6. Dulac O. Epileptic encephalopathy. Epilepsia 2001;42 Suppl 3:23-26.
7. Jeavons PM, Livet MO. West syndrome: infantile spasms. In: Roger J, Bureau M, Dravet C, Dreifuss FE, Perret A, Wolf P, (Eds). Epileptic Syndromes in Infancy, Childhood and Adolescence, 2 ed. London: John Libbey and Company, 1992:53-65.
8. Lux AL, Osborne JP. A proposal for case definitions and outcome measures in studies of infantile spasms and West syndrome: consensus statement of the West Delphi group. Epilepsia 2004;45:1416-1428.
9. Hrachovy RA, Frost JD, Jr., Kellaway P. Hypsarrhythmia: variations on the theme. Epilepsia 1984;25:317-325.
10. Dravet C, Bureau M, Guerrini R, Giraud N, Roger J. Severe myoclonic epilepsy in infancy. In: Roger J, Bureau M, Dravet C, Dreifuss FE, Perret A, Wolf P, (Eds). Epileptic Syndromes in Infancy, Childhood and Adolescence, 2 ed. London: John Libbey and Company, 1992:75-88.
11. Kanai K, Hirose S, Oguni H, et al. Effect of localization of missense mutations in SCN1A on epilepsy phenotype severity. Neurology 2004;63:329-334.
12. Beaumanoir A DC. The Lennox-Gastaut syndrome. In: Roger J, Bureau M, Dravet C, Dreifuss FE, Perret A, Wolf P, (Eds). Epileptic Syndromes in Infancy, Childhood and Adolescence, 2 ed. London: John Libbey and Company, 1992:115-132.
13. Goldsmith IL, Zupanc ML, Buchhalter JR. Long-term seizure outcome in 74 patients with Lennox-Gastaut syndrome: effects of incorporating MRI head imaging in defining the cryptogenic subgroup. Epilepsia 2000;41:395-399.
14. Dulac O, N'Guyen T. The Lennox-Gastaut syndrome. Epilepsia 1993;34 Suppl 7:87-17.
15. Markand ON. Lennox-Gastaut syndrome (childhood epileptic encephalopathy). J Clin Neurophysiol 2003;20:426-441.
16. Boniver C, Dravet C, Bureau M, Roger J. Idiopathic Lennox-Gastaut syndrome. Advances in Epileptology 1987;16:195-200.
17. Oguni H, Hayashi K, Osawa M. Long-term prognosis of Lennox-Gastaut syndrome. Epilepsia 1996;37 Suppl 3:44-47.
18. Doose H. Myoclonic astatic epilepsy of early childhood. In: Roger J, Bureau M, Dravet C, Dreifuss FE, Perret A, Wolf P, (Eds). Epileptic Syndromes of Infancy, Childhood and Adolescence, 2 ed. London: John Libbey and Company, 1992:103-114.
19. Scheffer IE, Wallace R, Mulley JC, Berkovic SF. Clinical and molecular genetics of myoclonic-astatic epilepsy and severe myoclonic epilepsy in infancy (Dravet syndrome). Brain Dev 2001;23:732-735.
20. Aicardi J. Myoclonic-astatic epilepsy. In: Wallace SJ, Farrell K, (Eds). Epilepsy in Children. London: Arnold, 2004;163-168.
21. Hahn A, Pistohl J, Neubauer BA, Stephani U. Atypical "benign" partial epilepsy or pseudo-Lennox syndrome. Part I: symptomatology and long-term prognosis. Neuropediatrics 2001;32:1-8.
22. Beaumanoir A. The Landau-Kleffner syndrome. In: Roger J, Bureau M, Dravet C, Dreifuss FE, Perret A, Wolf P, (Eds). Epileptic Syndromes in Infancy, Childhood and Adolescence, 2 ed. London: John Libbey and Company, 1992:231-243.
23. Tassinari CA, Bureau M, Dravet C, Dalla Bernardina B, Roger J. Epilepsy with continuous spikes and waves during slow sleep - otherwise described as ESES (epilepsy with electrical status epilepticus during slow sleep). In: Roger J, Bureau M, Dravet C, Dreifuss FE, Perret A, Wolf P, (Eds). Epileptic Syndromes in Infancy, Childhood and Adolescence, 2 ed. London: John Libbey and Company, 1992:245-256.
24. Jambaque I. Neuropsychological Aspects. In: Dulac O, Chugani HT, Dalla Bernardina B, (Eds). Infantile Spasms and West Syndrome, 1 ed. London: WB Saunders, 1994:82-87.
25. Kivity S, Lerman P, Ariel R, et al. Long-term cognitive outcomes of a cohort of children with cryptogenic infantile spasms treated with high-dose adrenocorticotropic hormone. Epilepsia 2004;45:255-262.
26. Riikonen R, Amnell G. Psychiatric disorders in children with earlier infantile spasms. Dev Med Child Neurol 1981;23:747-760.
27. Askalan R, Mackay M, Brian J, et al. Prospective preliminary analysis of the development of autism and epilepsy in children with infantile spasms. J Child Neurol 2003;18:165-170.
28. Hunt A, Dennis J. Psychiatric disorder among children with tuberous sclerosis. Dev Med Child Neurol 1987;29:190-198.
29. Bolton PF. Neuroepileptic correlates of autistic symptomatology in tuberous sclerosis. Ment Retard Dev Disabil Res Rev 2004;10:126-131.
30. Casse-Perrot C, Wolf M, Dravet C. Neuropsychological aspects of severe myoclonic epilepsy in infancy. In: Jambaque I, Lassonde M, Dulac O, (Eds). Neuropsychology of Childhood Epilepsy, 1 ed. New York: Kluwer Academic/Plenum Publishers, 2005:131-140.
31. Boel MJ. Behavioural and neuropsychological problems in refractory paediatric epilepsies. Eur J Paediatr Neurol 2004;8:291-297.
32. Kieffer-Renaux V, Kaminska A, Dulac O. Cognitive deterioration in Lennox-Gastaut syndrome and Doose epilepsy. In: Jambaque I, Lassonde M, Dulac O, (Eds). Neuropsychology of Childhood Epilepsy, 1 ed. New York: Kluwer Academic/Plenum, 2001:185-190.
33. Blume WT, David RB, Gomez MR. Generalized sharp and slow wave complexes: associated clinical features and long-term follow-up. Brain 1973;96:289-306.
34. Loring DW, Meador KJ. Cognitive side effects of antiepileptic drugs in children. Neurology 2004;62:872-877.
35. Camfield CS, Chaplin S, Doyle AB, et al. Side effects of phenobarbital in toddlers; behavioral and cognitive aspects. J Pediatr 1979;95:361-365.
36. Hellstrom B, Barlach-Christoffersen M. Influence of phenobarbital on the psychomotor development and behaviour in preschool children with convulsions. Neuropadiatrie 1980;11:151-160.
37. Farwell JR, Lee YJ, Hirtz DG, Sulzbacher SI, Ellenberg JH, Nelson KB. Phenobarbital for febrile seizures-effects on intelligence and on seizure recurrence. N Engl J Med 1990;322:364-369.
38. Stores G, Williams PL, Styles E, Zaiwalla Z. Psychological effects of sodium valproate and carbamazepine in epilepsy. Arch Dis Child 1992;67:1330-1337.
39. Forsythe I, Butler R, Berg I, McGuire R. Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Dev Med Child Neurol 1991;33:524-534.
40. Gallassi R, Morreale A, Di SR, et al. Cognitive effects of antiepileptic drug discontinuation. Epilepsia 1992;33 Suppl 6:S41-S44.
41. Aldenkamp AP, Alpherts WC, Blennow G, et al. Withdrawal of antiepileptic medication in children-effects on cognitive function: The Multicenter Holmfrid Study. Neurology 1993;43:41-50.
42. Elterman RD, Glauser TA, Wyllie E, et al. A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Topiramate YP Study Group. Neurology 1999;52:1338-1344.
43. Aldenkamp AP, Arends J. Effects of epileptiform EEG discharges on cognitive function: is the concept of "transient cognitive impairment" still valid? Epilepsy Behav 2004;5 Suppl 1:S25-S34.
44. Kasteleijn-Nolst Trenite DG. Transient cognitive impairment during subclinical epileptiform electroencephalographic discharges. Semin Pediatr Neurol 1995;2:246-253.
45. Stores G, Zaiwalla Z, Styles E, Hoshika A. Non-convulsive status epilepticus. Arch Dis Child 1995;73:106-111.
46. Manning DJ, Rosenbloom L. Non-convulsive status epilepticus. Arch Dis Child 1987;62:37-40.
47. Hoffmann-Riem M, Diener W, Benninger C, et al. Nonconvulsive status epilepticus-a possible cause of mental retardation in patients with Lennox-Gastaut syndrome. Neuropediatrics 2000;31:169-174.
48. Tassinari CA, Daniele O, Michelucci R, et al. Benzodiazepines: efficacy in status epilepticus. Adv Neurol 1983;34:465-475.
49. Livingston JH, Brown JK. Non-convulsive status epilepticus resistant to benzodiazepines. Arch Dis Child 1987;62:41-44.
50. Tassinari CA, Dravet C, Roger J, Cano JP, Gastaut H. Tonic status epilepticus precipitated by intravenous benzodiazepine in five patients with Lennox-Gastaut syndrome. Epilepsia 1972;13:421-435.
51. Shields WD, Saslow E. Myoclonic, atonic, and absence seizures following institution of carbamazepine therapy in children. Neurology 1983;33:1487-1489.
52. Lerman P. Seizures induced or aggravated by anticonvulsants. Epilepsia 1986;27:706-710.
53. Snead OC, III, Hosey LC. Exacerbation of seizures in children by carbamazepine. N Engl J Med 1985;313:916-921.
54. Osorio I, Reed RC, Peltzer JN. Refractory idiopathic absence status epilepticus: A probable paradoxical effect of phenytoin and carbamazepine. Epilepsia 2000;41:887-894.
55. Viani F, Romeo A, Viri M, et al. Seizure and EEG patterns in Angelman's syndrome. J Child Neurol 1995;10:467-471.
56. Corda D, Gelisse P, Genton P, Dravet C, Baldy-Moulinier M. Incidence of drug-induced aggravation in benign epilepsy with centrotemporal spikes. Epilepsia 200;42:754-759.
57. Eldridge R, Iivanainen M, Stern R, Koerber T, Wilder BJ. "Baltic" myoclonus epilepsy: hereditary disorder of childhood made worse by phenytoin. Lancet 1983;2:838-842.
58. Guerrini R, Dravet C, Genton P, et al. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 1998;39:508-512.
59. Ettinger AB, Bernal OG, Andriola MR, et al. Two cases of nonconvulsive status epilepticus in association with tiagabine therapy. Epilepsia 1999;40:1159-1162.
60. Vossler DG. Exacerbation of seizures in Lennox-Gastaut syndrome by gabapentin. Neurology 1996;46:852-853.
61. Hancock E, Osborne JP. Vigabatrin in the treatment of infantile spasms in tuberous sclerosis: literature review. J Child Neurol 1999;14:71-74.
62. Jambaque I, Chiron C, Dumas C, Mumford J, Dulac O. Mental and behavioural outcome of infantile epilepsy treated by vigabatrin in tuberous sclerosis patients. Epilepsy Res 2000;38:151-160.
63. Chiron C, Marchand MC, Tran A, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet 2000;356:1638-1642.
64. Coppola G, Capovilla G, Montagnini A, et al. Topiramate as add-on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial. Epilepsy Res 2002;49:45-48.
65. Brown P, Steiger MJ, Thompson PD, et al. Effectiveness of piracetam in cortical myoclonus. Mov Disord 1993;8:63-68.
66. Genton P, Guerrini R, Remy C. Piracetam in the treatment of cortical myoclonus. Pharmacopsychiatry 1999;32 Suppl 1:49-53.
67. Ikeda A, Shibasaki H, Tashiro K, Mizuno Y, Kimura J. Clinical trial of piracetam in patients with myoclonus: nationwide multiinstitution study in Japan. The Myoclonus/Piracetam Study Group. Mov Disord 1996 Nov;11(6):691-700.
68. Guerrini R, De Lorey TM, Bonanni P, et al. Cortical myoclonus in Angelman syndrome. Ann Neurol 1996 Jul;40(1):39-48.
69. Conry JA RSea. Efficacy of zonisamide in progressive myoclonic epilepsy: a case series. Ann Neurol 2001;50 (suppl 3):S104Abs.
70. Kyllerman M, Ben-Menachem E. Zonisamide for progressive myoclonus epilepsy: long-term observations in seven patients. Epilepsy Res 1998;29:109-114.
71. Rating D, Wolf C, Bast T. Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6-month randomized, double-blind, placebo-controlled study. Sulthiame Study Group. Epilepsia 2000;41:1284-1288.
72. Baxter P, Griffiths P, Kelly T, Gardner-Medwin D. Pyridoxine-dependent seizures: demographic, clinical, MRI and psychometric features, and effect of dose on intelligence quotient. Dev Med Child Neurol 1996;38:998-1006.
73. Torres OA, Miller VS, Buist NM, Hyland K. Folinic acid-responsive neonatal seizures. J Child Neurol 1999;14:529-532.
74. Wolf B, Heard GS, Weissbecker KA, et al. Biotinidase deficiency: initial clinical features and rapid diagnosis. Ann Neurol 1985;18:614-617.
75. Eriksson AS, Nergardh A, Hoppu K. The efficacy of lamotrigine in children and adolescents with refractory generalized epilepsy: a randomized, double-blind, crossover study. Epilepsia 1998;39:495-501.
76. Sachdeo RC, Glauser TA, Ritter F, et al. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology 1999;52:1882-1887.
77. Coppola G, Caliendo G, Veggiotti P, et al. Topiramate as add-on drug in children, adolescents and young adults with Lennox-Gastaut syndrome: an Italian multicentric study. Epilepsy Res 2002;51:147-153.
78. Motte J, Trevathan E, Arvidsson JF, et al. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. N Engl J Med 1997;337:1807-1812.
79. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). The Felbamate Study Group in Lennox-Gastaut Syndrome. N Engl J Med 1993;328:29-33.
80. Hancock E, Cross H. Treatment of Lennox-Gastaut syndrome. Cochrane Database Syst Rev 2003;(3):CD003277.
81. Mackay MT, Weiss SK, ms-Webber T, et al. Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society. Neurology 2004 May 25;62(10):1668-1681.
82. Hrachovy RA, Frost JD, Jr., Kellaway P, Zion TE. Double-blind study of ACTH vs prednisone therapy in infantile spasms. J Pediatr 1983;103:641-645.
83. Baram TZ, Mitchell WG, Tournay A, et al. High-dose corticotropin (ACTH) versus prednisone for infantile spasms: a prospective, randomized, blinded study. Pediatrics 1996;97:375-379.
84. Snead OC, III, Benton JW, Myers GJ. ACTH and prednisone in childhood seizure disorders. Neurology 1983;33:966-970.
85. Hrachovy RA, Frost JD, Jr., Glaze DG. High-dose, long-duration versus low-dose, short-duration corticotropin therapy for infantile spasms. J Pediatr 1994;124(5 Pt 1):803-806.
86. Yanagaki S, Oguni H, Hayashi K, et al. A comparative study of high-dose and low-dose ACTH therapy for West syndrome. Brain Dev 1999;21:461-467.
87. Lombroso CT. A prospective study of infantile spasms: clinical and therapeutic correlations. Epilepsia 1983;24:135-158.
88. Marescaux C, Hirsch E, Finck S, et al. Landau-Kleffner syndrome: a pharmacologic study of five cases. Epilepsia 1990;31:768-777.
89. Lerman P, Lerman-Sagie T, Kivity S. Effect of early corticosteroid therapy for Landau-Kleffner syndrome. Dev Med Child Neurol 1991;33:257-260.
90. Tsuru T, Mori M, Mizuguchi M, Momoi MY. Effects of high-dose intravenous corticosteroid therapy in Landau-Kleffner syndrome. Pediatr Neurol 2000;22:145-147.
91. Yamatogi Y, Ohtsuka Y, Ishida T, et al. Treatment of the Lennox syndrome with ACTH: a clinical and electroencephalographic study. Brain Dev 1979;1:267-276.
92. van Rijckevorsel-Harmant K, Delire M, Schmitz-Moorman W, Wieser HG. Treatment of refractory epilepsy with intravenous immunoglobulins. Results of the first double-blind/dose finding clinical study. Int J Clin Lab Res 1994;24:162-166.
93. Illum N, Taudorf K, Heilmann C, et al. Intravenous immunoglobulin: a single-blind trial in children with Lennox-Gastaut syndrome. Neuropediatrics 1990;21:87-90.
94. Freeman JM, Vining EP, Pillas DJ, et al. The efficacy of the ketogenic diet-1998: a prospective evaluation of intervention in 150 children. Pediatrics 1998;102:1358-1363.
95. Vining EP, Freeman JM, Ballaban-Gil K, et al. A multicenter study of the efficacy of the ketogenic diet. Arch Neurol 1998;55:1433-1437.
96. Lefevre F, Aronson N. Ketogenic diet for the treatment of refractory epilepsy in children: A systematic review of efficacy. Pediatrics 2000;105:E46.
97. Nordli DR, Jr., Kuroda MM, Carroll J, et al. Experience with the ketogenic diet in infants. Pediatrics 2001;108:129-133.
98. Kossoff EH, Pyzik PL, McGrogan JR, Vining EP, Freeman JM. Efficacy of the ketogenic diet for infantile spasms. Pediatrics 2002;109:780-783.
99. Oguni H, Tanaka T, Hayashi K, et al. Treatment and long-term prognosis of myoclonic-astatic epilepsy of early childhood. Neuropediatrics 2002;33:122-132.
100. Fejerman N, Caraballo R, Cersosimo R. Ketogenic diet in patients with Dravet syndrome and myoclonic epilepsies in infancy and early childhood. Adv Neurol 2005;95:299-305.
101. Moreno Villares JM, Oliveros-Leal L, Simon-Heras R, Mateos-Beato F. [The return to the ketogenic diet. What role does it play in the treatment of refractory seizures of infancy?]. Rev Neurol 2001;32:1115-1119.
102. Pulsifer MB, Gordon JM, Brandt J, Vining EP, Freeman JM. Effects of ketogenic diet on development and behavior: preliminary report of a prospective study. Dev Med Child Neurol 2001;43:301-306.
103. Chugani HT, Shewmon DA, Shields WD, et al. Surgery for intractable infantile spasms: neuroimaging perspectives. Epilepsia 1993;34:764-771.
104. Asarnow RF, LoPresti C, Guthrie D, et al. Developmental outcomes in children receiving resection surgery for medically intractable infantile spasms. Dev Med Child Neurol 1997;39:430-440.
105. Chugani DC, Chugani HT, Muzik O, et al. Imaging epileptogenic tubers in children with tuberous sclerosis complex using alpha-[11C]methyl-L-tryptophan positron emission tomography. Ann Neurol 1998;44:858-866.
106. Quarato PP, Gennaro GD, Manfredi M, Esposito V. Atypical Lennox-Gastaut syndrome successfully treated with removal of a parietal dysembryoplastic tumour. Seizure 2002;11:325-329.
107. Morrell F, Whisler WW, Smith MC, et al. Landau-Kleffner syndrome. Treatment with subpial intracortical transection. Brain 1995;118:1529-1546.
108. Buelow JM, Aydelott P, Pierz DM, Heck B. Multiple subpial transection for Landau-Kleffner syndrome. AORN J 1996;63:727-735, 737.
109. Irwin K, Birch V, Lees J, et al. Multiple subpial transection in Landau-Kleffner syndrome. Dev Med Child Neurol 2001;43:248-252.
110. Grote CL, Van SP, Hoeppner JA. Language outcome following multiple subpial transection for Landau-Kleffner syndrome. Brain 1999;122:561-566.
111. Cendes F, Ragazzo PC, da C, V, Martins LF. Corpus callosotomy in treatment of medically resistant epilepsy: preliminary results in a pediatric population. Epilepsia 1993;34:910-917.
112. McInerney J, Siegel AM, Nordgren RE, et al. Long-term seizure outcome following corpus callosotomy in children. Stereotact Funct Neurosurg 1999;73:79-83.
113. Parker AP, Polkey CE, Binnie CD, et al. Vagal nerve stimulation in epileptic encephalopathies. Pediatrics 1999;103:778-782.
114. Aldenkamp AP, Majoie HJM, Berfelo MW, et al. Long-term effects of 24-month treatment with vagus nerve stimulation on behaviour in children with Lennox-Gastaut syndrome. Epilepsy Behav 2002;3:475-479Abs.
115. Frost M, Gates J, Helmers SL, et al. Vagus nerve stimulation in children with refractory seizures associated with Lennox-Gastaut syndrome. Epilepsia 2001;42:1148-1152.
116. Hosain S, Nikalov B, Harden C, Li M, Faser R, Labar D. Vagus nerve stimulation treatment for Lennox-Gastaut syndrome. J Child Neurol 2000;15:509-512.
117. Hornig GW, Murphy JV, Schallert G, Tilton C. Left vagus nerve stimulation in children with refractory epilepsy: an update. South Med J 1997;90:484-488.